Pharma Mar SA (ES:PHM) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Pharma Mar SA has successfully recruited 705 patients for its phase III LAGOON clinical trial, which evaluates the efficacy of Zepzelca® (lurbinectedin) in treating small cell lung cancer. This significant milestone reflects the company’s ongoing commitment to expanding treatment options, with preliminary results anticipated in early 2026. The trial aims to assess overall and progression-free survival, contributing to the growing body of research on advanced cancer therapies.
For further insights into ES:PHM stock, check out TipRanks’ Stock Analysis page.
